AstraZeneca has admitted that a mistake had been made in the coronavirus trials conducted by the company. This has caused a certain amount of confusion as well as a drop in its share prices as reports say that this may hamper its FDA early approval.
AstraZeneca had created waves initially by saying that its vaccine would be much cheaper than the ones developed by Pfizer and Moderna as well as it would be easier to store.
However the UK pharmaceutical company, along with its partner Oxford University, said that a mistake had been made. After getting 90% positive results, they realized that a batch of the volunteers had been given half doses but showed better results than the main group of volunteers who were given the correct two doses but showed 62% efficacy.
Natalie Dean, a biostatistician and expert in vaccine trial design from the University of Florida wrote, “It is awfully confusing for experts and non experts alike.” She gave Team UK vaccine “a poor grade for transparency and rigor,” on Twitter.
Analysts and scientists alike have been disappointed with the handling of the issue as well as the mistake though the lead researcher at AstraZeneca called it “serendipity.”
A spokesperson for AstraZeneca Michele Meixell said that the trials were conducted “to the highest standard,” and added that more analysis is being carried out to refine the efficacy results.
This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.